keyword
MENU ▼
Read by QxMD icon Read
search

DPP4I

keyword
https://www.readbyqxmd.com/read/29760346/effect-of-sitagliptin-on-coronary-flow-reserve-assessed-by-magnetic-resonance-imaging-in-type-2-diabetic-patients-with-coronary-artery-disease
#1
Keishi Moriwaki, Tetsushiro Takeuchi, Naoki Fujimoto, Toshiki Sawai, Yuichi Sato, Naoto Kumagai, Jun Masuda, Shiro Nakamori, Masaki Ishida, Norikazu Yamada, Mashio Nakamura, Hajime Sakuma, Masaaki Ito, Kaoru Dohi
BACKGROUND: The present study was conducted to assess the cardiovascular effects of dipeptidyl peptidase-4 inhibitors (DPP4i) on coronary flow reserve (CFR), left ventricular (LV) function and endothelial function of the peripheral artery by comparison with those of α-glucosidase inhibitors (αGI) in patients with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD).Methods and Results:We randomly assigned 30 patients with T2DM and CAD to receive either sitagliptin or voglibose, and 28 patients (age 69±9 years, 75% male, hemoglobin A1c [HbA1c] 6...
May 12, 2018: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/29706950/bullous-pemphigoid-triggered-by-thermal-burn-under-medication-with-a-dipeptidyl-peptidase-iv-inhibitor-a-case-report-and-review-of-the-literature
#2
Yosuke Mai, Wataru Nishie, Kazumasa Sato, Moeko Hotta, Kentaro Izumi, Kei Ito, Kazuyoshi Hosokawa, Hiroshi Shimizu
Bullous pemphigoid (BP) is a common autoimmune blistering disease in which autoantibodies mainly target the hemidesmosomal component BP180 (also known as type XVII collagen) in basal keratinocytes. Various triggering factors are known to induce BP onset, including radiotherapy, burns, ultraviolet exposure, surgery, and the use of dipeptidyl peptidase-IV inhibitors (DPP4i), which are widely used antihyperglycemic drugs. Here, we present a case of BP triggered by a thermal burn under medication with DPP4i. A 60-year-old man with type II diabetes had been treated with the DPP4i linagliptin for 1 year...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29556215/clinical-and-physiological-characterization-of-elevated-plasma-glucagon-like-peptide-1-levels-hyperglipemia-in-a-dipeptidyl-peptidase-iv-mutation-carrier
#3
Dandan Zhao, Shaoqian Zhao, Xiao Wang, Mingbo Su, Wen Liu, Qinyun Ma, Jie Hong, Weiqiong Gu, Jingya Li, Ruixin Liu, Guang Ning, Jiqiu Wang, Yifei Zhang
The clinical application of dipeptidyl peptidase IV inhibitors (DPP4i) increasing active glucagon-like peptide-1 (AGLP-1) levels has been linked to pancreatitis, pancreatic tumors, and cardiovascular events. However, DPP4 mutations in humans or the long-term outcomes of high glucagon-like peptide-1 (GLP-1) level exposure have not been reported. A trio family with a proband showing an extremely high AGLP-1 level [defined here as hyperglipemia (hyper-glucagon-like peptide-1-emia)] were conducted whole-exome sequencing for potential pathogenic genetic defects...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29549573/pharmacovigilance-evaluation-of-the-association-between-dpp-4-inhibitors-and-heart-failure-stimulated-reporting-and-moderation-by-drug-interactions
#4
Gian Paolo Fadini, Mayur Sarangdhar, Angelo Avogaro
INTRODUCTION: In the SAVOR-TIMI trial, the risk of heart failure (HF) was increased by 27% in T2D patients randomized to the dipeptidyl peptidase-4 inhibitor (DPP4i) saxagliptin. Other studies have provided inconsistent results regarding this association. Herein, we performed a pharmacovigilance analysis of the rate of HF associated with DPP4is, focusing on stimulated reporting and moderation by drug-drug interactions. METHODS: We mined the FDA adverse event (AE) reporting system (FAERS) from 2004q1 to 2017q3, including a total of 9906,642 AE reports...
April 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29535389/combination-of-sodium-glucose-cotransporter-2-inhibitor-and-dipeptidyl-peptidase-4-inhibitor-in-type-2-diabetes-a-systematic-review-with-meta-analysis
#5
Se Hee Min, Jeong-Hwa Yoon, Sun Joon Moon, Seokyung Hahn, Young Min Cho
Sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors have complementary mode of action. For the meta-analysis comparing the efficacy and safety between SGLT2 inhibitor plus DPP4 inhibitor (SGLT2i/DPP4i) and placebo plus DPP4 inhibitor (PCB/DPP4i) in patients with type 2 diabetes mellitus (T2DM), we selected randomized controlled trials from electronic databases by predefined criteria. The primary outcome of interest was the change in glycated hemoglobin A1c (HbA1c) from baseline...
March 13, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29530797/metformin-combined-with-dipeptidyl-peptidase-4-inhibitors-or-metformin-combined-with-sulfonylureas-in-patients-with-type-2-diabetes-a-real-world-analysis-of-the-south-korean-national-cohort
#6
Yeon Young Cho, Sung-Il Cho
AIMS: We explored the risks associated with metformin plus sulfonylurea (MET+SU) or MET plus a dipeptidyl peptidase-4 inhibitor (MET+DPP4i) for hypoglycemia, cardiovascular disease (CVD) events and all-cause mortality in type 2 diabetes (T2D) patients with comorbidities. METHODS: This retrospective cohort study is based on the South Korean National Health Insurance Service-National Sample Cohort, enrolling T2D patients with one or more diabetes-related comorbidities who switched from monotherapy to MET+SU or MET+DPP4i between July 1, 2008 and December 31, 2013...
March 9, 2018: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/29511288/comparison-of-non-insulin-antidiabetic-agents-as-an-add-on-drug-to-insulin-therapy-in-type-2-diabetes-a-network-meta-analysis
#7
Jeong-Hwa Yoon, Se Hee Min, Chang Ho Ahn, Young Min Cho, Seokyung Hahn
We aimed to evaluate the comparative efficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP4i), glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium-glucose co-transporter 2 inhibitors (SGLT2i), or thiazolidinedione (TZD) as an adjunctive treatment in patients with poorly controlled type 2 diabetes mellitus (T2DM) on insulin therapy. We searched Medline, Embase, the Cochrane Library, and ClinicalTrials.gov through April 2016. Bayesian network meta-analyses were performed with covariate adjustment...
March 6, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29508169/combined-sglt2-and-dpp4-inhibition-reduces-the-activation-of-the-nlrp3-asc-inflammasome-and-attenuates-the-development-of-diabetic-nephropathy-in-mice-with-type-2-diabetes
#8
Yochai Birnbaum, Mandeep Bajaj, Hsiu-Chiung Yang, Yumei Ye
BACGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 inhibitors (DPP4I) are used to treat type 2 diabetes (T2DM). DPP4 inhibitors (DPP4) attenuate Nlrp3 inflammasome activation in the kidney. SGLT2 inhibition reduces inflammation and attenuates the progression of diabetic nephropathy (DN). The effects of dapagliflozin (Dapa) on the activation of the Nlrp3 inflammasome and the combined effect of SGLT2 and DPP4 on T2DM-induced inflammasome activation and progression of DN have not been previously studied...
March 5, 2018: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29449146/efficacy-and-safety-of-combination-therapy-with-sglt2-and-dpp4-inhibitors-in-the-treatment-of-type-2-diabetes-a-systematic-review-and-meta-analysis
#9
Y K Cho, Y M Kang, S E Lee, J Lee, J-Y Park, W J Lee, Y-J Kim, C H Jung
BACKGROUND: This review evaluated the efficacy and safety of a combination therapy comprising a sodium-glucose cotransporter type 2 inhibitor (SGLT2i) and dipeptidyl peptidase-4 inhibitor (DPP4i) in type 2 diabetes. METHODS: A literature search through to May 2017 was carried out of PubMed, Embase and the Cochrane Central Register of Controlled Trials. Studies were eligible if they were randomized controlled trials (RCTs) comparing SGLT2i plus DPP4i (SGLT2i/DPP4i) against DPP4i±placebo or SGLT2i±placebo and published in English...
February 3, 2018: Diabetes & Metabolism
https://www.readbyqxmd.com/read/29446164/dipeptidyl-peptidase-4-inhibitor-associated-bullous-pemphigoid-in-a-patient-with-acquired-reactive-perforating-collagenosis
#10
Nobuki Maki, Wataru Nishie, Maya Takazawa, Maki Kakurai, Tomoko Yamada, Naoka Umemoto, Masaaki Kawase, Kentaro Izumi, Hiroshi Shimizu, Toshio Demitsu
Bullous pemphigoid (BP) is a common autoimmune blistering disorder with unknown etiology. Recently, increasing numbers of BP cases which developed under the medication with dipeptidyl peptidase-4 inhibitors (DPP4i), widely used antihyperglycemic drugs, have been reported in published works. Here, we report a case of DPP4i (teneligliptin)-associated BP that developed in a 70-year-old Japanese man. Interestingly, the patient had acquired reactive perforating collagenosis (ARPC), which is also known to be associated with the onset of BP...
May 2018: Journal of Dermatology
https://www.readbyqxmd.com/read/29299596/clinical-and-immunological-profiles-of-14-patients-with-bullous-pemphigoid-without-igg-autoantibodies-to-the-bp180-nc16a-domain
#11
Kenta Nakama, Hiroshi Koga, Norito Ishii, Chika Ohata, Takashi Hashimoto, Takekuni Nakama
Importance: Enzyme-linked immunosorbent assay (ELISA) and/or chemiluminescent enzyme immunoassay (CLEIA) for BP180 noncollagenous 16A (NC16A) extracellular domain is a sensitive diagnostic tool for bullous pemphigoid (BP). However, some patients with BP have negative results for these assays. Objective: To elucidate the clinical and immunological features of patients with BP without antibodies that react to BP180 NC16A. Design, Setting, and Participants: This retrospective case series study included 152 patients who were diagnosed with BP and followed up at the Kurume University Hospital in Japan from 2007 to 2016...
March 1, 2018: JAMA Dermatology
https://www.readbyqxmd.com/read/29279487/changes-in-antidiabetic-drug-prescription-and-glycemic-control-trends-in-elderly-patients-with-type-2-diabetes-mellitus-from-2005-2013-an-analysis-of-the-national-center-diabetes-database-ncdd-03
#12
Ritsuko Yamamoto-Honda, Yoshihiko Takahashi, Yasumichi Mori, Shigeo Yamashita, Yoko Yoshida, Shoji Kawazu, Yasuhiko Iwamoto, Hiroshi Kajio, Hidekatsu Yanai, Shuichi Mishima, Nobuhiro Handa, Kotaro Shimokawa, Akiko Yoshida, Hiroki Watanabe, Kazuhiko Ohe, Takuro Shimbo, Mitsuhiko Noda
Objective To analyze the changes in the pharmacotherapy and glycemic control trends in elderly patients with type 2 diabetes mellitus (T2DM) in Japan. Materials and Methods We extracted the data of 7,590 patients (5,396 men and 2,194 women; median year of birth: 1945) with T2DM registered in the National Center Diabetes Database for the years 2005 to 2013, and conducted age-stratified (<65, 65-74, and ≥75 years of age) analyses. Results The hemoglobin A1c (HbA1c) levels declined from 2005 to 2013, and for those who received antihyperglycemic drug prescription, the HbA1c levels were lower in the older age group than in the younger age group...
December 27, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29274348/dipeptidyl-peptidase-iv-inhibitors-a-risk-factor-for-bullous-pemphigoid-retrospective-multicenter-case-control-study-from-france-and-switzerland
#13
Michael Benzaquen, Luca Borradori, Philippe Berbis, Simone Cazzaniga, René Valero, Marie-Aleth Richard, Laurence Feldmeyer
BACKGROUND: Case reports have suggested an association between dipeptidyl peptidase-4 inhibitors (DPP4is) and development of bullous pemphigoid (BP). OBJECTIVE: To evaluate the association between DPP4i treatment and development of BP. METHODS: We conducted a retrospective 1:2 case-control study, comparing case patients with diabetes and BP with age- and sex-matched control patients with diabetes issued from Swiss (Bern) and French (Marseille) dermatologic departments from January 1, 2014, to July 31, 2016...
December 21, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29258504/dipeptidyl-peptidase-4-inhibitor-decreases-the-risk-of-atrial-fibrillation-in-patients-with-type-2-diabetes-a-nationwide-cohort-study-in-taiwan
#14
Chia-Yu Chang, Yung-Hsin Yeh, Yi-Hsin Chan, Jia-Rou Liu, Shang-Hung Chang, Hsin-Fu Lee, Lung-Sheng Wu, Kun-Chi Yen, Chi-Tai Kuo, Lai-Chu See
BACKGROUND: Whether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF associated with use of DPP4i among a longitudinal cohort of patients with diabetes. METHODS: Over a 3-year period, 480,000 patients with diabetes were analyzed utilizing Taiwan's National Health Insurance Research Database and 90,880 patients taking metformin as first-line therapy were enrolled...
December 19, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29172255/relationship-between-deterioration-of-glycated-hemoglobin-lowering-effects-in-dipeptidyl-peptidase-4-inhibitor-monotherapy-and-dietary-habits-retrospective-analysis-of-japanese-individuals-with-type-2-diabetes
#15
Hitoshi Kuwata, Saki Okamoto, Yusuke Seino, Kenta Murotani, Hisato Tatsuoka, Ryota Usui, Yoshiyuki Hamamoto, Takeshi Kurose, Yutaka Seino, Daisuke Yabe
The present study was designed to assess possible relationships between deterioration of the glycated hemoglobin (HbA1c)-lowering effects in dipeptidyl peptidase-4 inhibitor (DPP4i) monotherapy and macronutrient intake among individuals with type 2 diabetes. Type 2 diabetes patients who began and continued DPP4i monotherapy without any prescription change for 1 year were retrospectively stratified into two groups: (i) patients who maintained their HbA1c levels during the 0.5- to 1-year period after DPP4i initiation (group A, ΔHbA1c [1-0...
November 24, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29171700/practical-strategies-for-improving-outcomes-in-t2dm-the-potential-role-of-pioglitazone-and-dpp4-inhibitors
#16
REVIEW
Stefano Del Prato, Robert Chilton
T2DM is a complex disease underlined by multiple pathogenic defects responsible for the development and progression of hyperglycaemia. Each of these factors can now be tackled in a more targeted manner thanks to glucose-lowering drugs that have been made available in the past 2 to 3 decades. Recognition of the multiplicity of the mechanisms underlying hyperglycaemia calls for treatments that address more than 1 of these mechanisms, with more emphasis placed on the earlier use of combination therapies. Although chronic hyperglycaemia contributes to and amplifies cardiovascular risk, several trials have failed to show a marked effect from intensive glycaemic control...
April 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29108837/factors-associated-with-type-2-diabetes-mellitus-treatment-choice-across-four-european-countries
#17
Edith M Heintjes, Jetty A Overbeek, Gillian C Hall, Daniel Prieto-Alhambra, Francesco Lapi, Niklas Hammar, Irene D Bezemer
PURPOSE: The aim of this analysis was to identify factors associated with the choice of type 2 diabetes mellitus (T2DM) therapy at the time of intensification of antidiabetic treatment across 4 European countries. METHODS: Antidiabetic drug prescription/dispensing records and patients' characteristics were obtained from the electronic health care records of patients with T2DM from the Netherlands (NL), Italy, and Spain (ES) (all, 2007-2011); and the United Kingdom (UK; 2008-2012)...
November 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29054111/dipeptidyl-peptidase-4-inhibitors-attenuates-the-decline-of-skeletal-muscle-mass-in-patients-with-type-2-diabetes
#18
Ryotaro Bouchi, Tatsuya Fukuda, Takato Takeuchi, Yujiro Nakano, Masanori Murakami, Isao Minami, Hajime Izumiyama, Koshi Hashimoto, Takanobu Yoshimoto, Yoshihiro Ogawa
BACKGROUND: Activation of dipeptidyl peptidase 4 has been reported to be associated with impairment of insulin signalling in skeletal muscle, presumably leading to loss of muscle function. This study was aimed to investigate whether the use of dipeptidyl peptidase 4 inhibitors (DPP4i) could attenuate the progressive loss of muscle mass in patients with type 2 diabetes. METHODS: A total 105 patients with type 2 diabetes (mean age 62 ± 12 years; 39% female) were studied in this retrospective observational study...
February 2018: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/29053207/dipeptidyl-peptidase-4-inhibitors-moderate-the-risk-of-genitourinary-tract-infections-associated-with-sodium-glucose-co-transporter-2-inhibitors
#19
Gian Paolo Fadini, Benedetta Maria Bonora, Sarangdhar Mayur, Mauro Rigato, Angelo Avogaro
Genitourinary tract infections (GUTIs) are the most common adverse event (AE) occurring during therapy with sodium-glucose co-transporter-2 (SGLT2) inhibitors. We evaluated whether dipeptidyl peptidase-4 inhibitors moderate the risk of GUTI during SGLT2 inhibitor therapy, using two approaches. First, we screened the literature for randomized controlled trials (RCTs) directly comparing the frequency of GUTIs in patients receiving DPP-4 inhibitor/SGLT2 inhibitor combination therapy vs those receiving an SGLT2 inhibitor only...
March 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29047219/addition-of-dipeptidyl-peptidase-4-inhibitors-to-insulin-treatment-in-type-2-diabetes-patients-a-meta-analysis
#20
Wenjia Yang, Xiaoling Cai, Xueying Gao, Yifei Chen, Ling Chen, Linong Ji
AIMS/INTRODUCTION: To evaluate the efficacy and safety of combining insulin therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors compared with combining insulin therapy with a placebo or other antihyperglycemic agents. MATERIALS AND METHODS: A literature search was carried out via electronic databases. The inclusion criteria were randomized controlled trials comparing the addition of DPP-4 inhibitors to insulin with the addition of a placebo or other active hypoglycemic agents to insulin therapy, study duration of no less than 12 weeks carried out in type 2 diabetes patients and the availability of outcome data to evaluate a change in the glycated hemoglobin...
October 19, 2017: Journal of Diabetes Investigation
keyword
keyword
69334
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"